Crewe Advisors LLC Inozyme Pharma, Inc. Transaction History
Crewe Advisors LLC
- $709 Million
- Q4 2024
Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
89Shares Held
53.3MCall Options Held
3.7KPut Options Held
5.8K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.67MShares$7.38 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$5.84 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$5.56 Million2.12% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.13MShares$5.37 Million0.38% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$5.16 Million1.97% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $52.2M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...